Research Paper Volume 16, Issue 3 pp 2789—2811

Figure 7. GSK2656157 enhances the antitumor activity of MPPα-PDT by inhibiting PERK pathway in vivo. HOS tumor-bearing mice were treated with MPPα (15 mg/kg), LED (120 J/mm2), GSK2656157 (30 mg/kg) and MPPα-PDT (LED following MPPα, as described in Materials and Methods). (A, B) After 31 days, tumors were collected. Tumor volume was determined as described in methods. (C) Tumor volume change curves. (D, E) After treatments, tumor necrosis and apoptosis were analyzed by H&E and TUNEL analysis, respectively (magnification, ×100). (F, G) After treatments, tumors apoptosis was assessed by cleaved caspase-3 western blot analysis. Data are shown as mean ± SD of 3 independent experiments. ^*P < 0.05.